203 related articles for article (PubMed ID: 25495129)
1. Identification of a novel orally bioavailable phosphodiesterase 10A (PDE10A) inhibitor with efficacy in animal models of schizophrenia.
Bartolomé-Nebreda JM; Alonso de Diego SA; Artola M; Delgado F; Delgado Ó; Martín-Martín ML; Martínez-Viturro CM; Pena MÁ; Tong HM; Van Gool M; Alonso JM; Fontana A; Macdonald GJ; Megens A; Langlois X; Somers M; Vanhoof G; Conde-Ceide S
J Med Chem; 2015 Jan; 58(2):978-93. PubMed ID: 25495129
[TBL] [Abstract][Full Text] [Related]
2. Discovery of a potent, selective, and orally active phosphodiesterase 10A inhibitor for the potential treatment of schizophrenia.
Bartolomé-Nebreda JM; Delgado F; Martín-Martín ML; Martínez-Viturro CM; Pastor J; Tong HM; Iturrino L; Macdonald GJ; Sanderson W; Megens A; Langlois X; Somers M; Vanhoof G; Conde-Ceide S
J Med Chem; 2014 May; 57(10):4196-212. PubMed ID: 24758746
[TBL] [Abstract][Full Text] [Related]
3. Discovery of pyrazolopyrimidine phosphodiesterase 10A inhibitors for the treatment of schizophrenia.
Raheem IT; Schreier JD; Fuerst J; Gantert L; Hostetler ED; Huszar S; Joshi A; Kandebo M; Kim SH; Li J; Ma B; McGaughey G; Sharma S; Shipe WD; Uslaner J; Vandeveer GH; Yan Y; Renger JJ; Smith SM; Coleman PJ; Cox CD
Bioorg Med Chem Lett; 2016 Jan; 26(1):126-32. PubMed ID: 26602277
[TBL] [Abstract][Full Text] [Related]
4. Discovery of imidazo[1,5-a]pyrido[3,2-e]pyrazines as a new class of phosphodiesterase 10A inhibitiors.
Höfgen N; Stange H; Schindler R; Lankau HJ; Grunwald C; Langen B; Egerland U; Tremmel P; Pangalos MN; Marquis KL; Hage T; Harrison BL; Malamas MS; Brandon NJ; Kronbach T
J Med Chem; 2010 Jun; 53(11):4399-411. PubMed ID: 20450197
[TBL] [Abstract][Full Text] [Related]
5. Discovery of benzo[d]imidazo[5,1-b]thiazole as a new class of phosphodiesterase 10A inhibitors.
Banerjee A; Narayana L; Raje FA; Pisal DV; Kadam PA; Gullapalli S; Kumar H; More SV; Bajpai M; Sangana RR; Jadhav S; Gudi GS; Khairatkar-Joshi N; Merugu RR; Voleti SR; Gharat LA
Bioorg Med Chem Lett; 2013 Dec; 23(24):6747-54. PubMed ID: 24231362
[TBL] [Abstract][Full Text] [Related]
6. The novel phosphodiesterase 10A inhibitor THPP-1 has antipsychotic-like effects in rat and improves cognition in rat and rhesus monkey.
Smith SM; Uslaner JM; Cox CD; Huszar SL; Cannon CE; Vardigan JD; Eddins D; Toolan DM; Kandebo M; Yao L; Raheem IT; Schreier JD; Breslin MJ; Coleman PJ; Renger JJ
Neuropharmacology; 2013 Jan; 64():215-23. PubMed ID: 22750078
[TBL] [Abstract][Full Text] [Related]
7. Evolution and synthesis of novel orally bioavailable inhibitors of PDE10A.
Burdi DF; Campbell JE; Wang J; Zhao S; Zhong H; Wei J; Campbell U; Shao L; Herman L; Koch P; Jones PG; Hewitt MC
Bioorg Med Chem Lett; 2015 May; 25(9):1864-8. PubMed ID: 25863433
[TBL] [Abstract][Full Text] [Related]
8. Discovery of tetrahydropyridopyrimidine phosphodiesterase 10A inhibitors for the treatment of schizophrenia.
Raheem IT; Breslin MJ; Fandozzi C; Fuerst J; Hill N; Huszar S; Kandebo M; Kim SH; Ma B; McGaughey G; Renger JJ; Schreier JD; Sharma S; Smith S; Uslaner J; Yan Y; Coleman PJ; Cox CD
Bioorg Med Chem Lett; 2012 Sep; 22(18):5903-8. PubMed ID: 22892116
[TBL] [Abstract][Full Text] [Related]
9. Highly potent, selective, and orally active phosphodiesterase 10A inhibitors.
Malamas MS; Ni Y; Erdei J; Stange H; Schindler R; Lankau HJ; Grunwald C; Fan KY; Parris K; Langen B; Egerland U; Hage T; Marquis KL; Grauer S; Brennan J; Navarra R; Graf R; Harrison BL; Robichaud A; Kronbach T; Pangalos MN; Hoefgen N; Brandon NJ
J Med Chem; 2011 Nov; 54(21):7621-38. PubMed ID: 21988093
[TBL] [Abstract][Full Text] [Related]
10. Discovery and Optimization of a Series of Pyrimidine-Based Phosphodiesterase 10A (PDE10A) Inhibitors through Fragment Screening, Structure-Based Design, and Parallel Synthesis.
Shipe WD; Sharik SS; Barrow JC; McGaughey GB; Theberge CR; Uslaner JM; Yan Y; Renger JJ; Smith SM; Coleman PJ; Cox CD
J Med Chem; 2015 Oct; 58(19):7888-94. PubMed ID: 26378882
[TBL] [Abstract][Full Text] [Related]
11. Triazoloquinazolines as a novel class of phosphodiesterase 10A (PDE10A) inhibitors.
Kehler J; Ritzen A; Langgård M; Petersen SL; Farah MM; Bundgaard C; Christoffersen CT; Nielsen J; Kilburn JP
Bioorg Med Chem Lett; 2011 Jun; 21(12):3738-42. PubMed ID: 21602043
[TBL] [Abstract][Full Text] [Related]
12. The SAR development of dihydroimidazoisoquinoline derivatives as phosphodiesterase 10A inhibitors for the treatment of schizophrenia.
Ho GD; Michael Seganish W; Bercovici A; Tulshian D; Greenlee WJ; Van Rijn R; Hruza A; Xiao L; Rindgen D; Mullins D; Guzzi M; Zhang X; Bleickardt C; Hodgson R
Bioorg Med Chem Lett; 2012 Apr; 22(7):2585-9. PubMed ID: 22377514
[TBL] [Abstract][Full Text] [Related]
13. Discovery of potent, selective, and metabolically stable 4-(pyridin-3-yl)cinnolines as novel phosphodiesterase 10A (PDE10A) inhibitors.
Hu E; Kunz RK; Rumfelt S; Chen N; Bürli R; Li C; Andrews KL; Zhang J; Chmait S; Kogan J; Lindstrom M; Hitchcock SA; Treanor J
Bioorg Med Chem Lett; 2012 Mar; 22(6):2262-5. PubMed ID: 22365755
[TBL] [Abstract][Full Text] [Related]
14. Design, optimization, and biological evaluation of novel keto-benzimidazoles as potent and selective inhibitors of phosphodiesterase 10A (PDE10A).
Hu E; Kunz RK; Chen N; Rumfelt S; Siegmund A; Andrews K; Chmait S; Zhao S; Davis C; Chen H; Lester-Zeiner D; Ma J; Biorn C; Shi J; Porter A; Treanor J; Allen JR
J Med Chem; 2013 Nov; 56(21):8781-92. PubMed ID: 24102193
[TBL] [Abstract][Full Text] [Related]
15. N-Acylhydrazones as inhibitors of PDE10A.
Gage JL; Onrust R; Johnston D; Osnowski A; Macdonald W; Mitchell L; Urögdi L; Rohde A; Harbol K; Gragerov S; Dormán G; Wheeler T; Florio V; Cutshall NS
Bioorg Med Chem Lett; 2011 Jul; 21(14):4155-9. PubMed ID: 21696955
[TBL] [Abstract][Full Text] [Related]
16. Novel benzimidazole derivatives as phosphodiesterase 10A (PDE10A) inhibitors with improved metabolic stability.
Chino A; Masuda N; Amano Y; Honbou K; Mihara T; Yamazaki M; Tomishima M
Bioorg Med Chem; 2014 Jul; 22(13):3515-26. PubMed ID: 24837154
[TBL] [Abstract][Full Text] [Related]
17. Novel 2-methoxyacylhydrazones as potent, selective PDE10A inhibitors with activity in animal models of schizophrenia.
Cutshall NS; Onrust R; Rohde A; Gragerov S; Hamilton L; Harbol K; Shen HR; McKee S; Zuta C; Gragerova G; Florio V; Wheeler TN; Gage JL
Bioorg Med Chem Lett; 2012 Sep; 22(17):5595-9. PubMed ID: 22841436
[TBL] [Abstract][Full Text] [Related]
18. Design and synthesis of novel benzimidazole derivatives as phosphodiesterase 10A inhibitors with reduced CYP1A2 inhibition.
Hamaguchi W; Masuda N; Isomura M; Miyamoto S; Kikuchi S; Amano Y; Honbou K; Mihara T; Watanabe T
Bioorg Med Chem; 2013 Dec; 21(24):7612-23. PubMed ID: 24238902
[TBL] [Abstract][Full Text] [Related]
19. Synthesis and SAR study of new phenylimidazole-pyrazolo[1,5-c]quinazolines as potent phosphodiesterase 10A inhibitors.
Asproni B; Murineddu G; Pau A; Pinna GA; Langgård M; Christoffersen CT; Nielsen J; Kehler J
Bioorg Med Chem; 2011 Jan; 19(1):642-9. PubMed ID: 21087867
[TBL] [Abstract][Full Text] [Related]
20. N-Methylanilide and N-methylbenzamide derivatives as phosphodiesterase 10A (PDE10A) inhibitors.
Kilburn JP; Kehler J; Langgård M; Erichsen MN; Leth-Petersen S; Larsen M; Christoffersen CT; Nielsen J
Bioorg Med Chem; 2013 Oct; 21(19):6053-62. PubMed ID: 23978358
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
